Literature DB >> 12731699

Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003.

.   

Abstract

CDC and the World Health Organization (WHO) are continuing to investigate the multicountry outbreak of severe acute respiratory syndrome (SARS). Infection with a novel coronavirus has been implicated as a possible cause of SARS. This report updates information on U.S. residents with SARS and summarizes the clinical histories of the five U.S. residents identified as of April 9, 2003, who have both suspected SARS and laboratory evidence of infection with a novel coronavirus.

Entities:  

Mesh:

Year:  2003        PMID: 12731699

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  30 in total

1.  Health-care provider preferences for time-sensitive communications from public health agencies.

Authors:  Debra Revere; Ian Painter; Mark Oberle; Janet G Baseman
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

Review 2.  Public health emergency preparedness and response communications with health care providers: a literature review.

Authors:  Debra Revere; Kailey Nelson; Hanne Thiede; Jeffrey Duchin; Andy Stergachis; Janet Baseman
Journal:  BMC Public Health       Date:  2011-05-18       Impact factor: 3.295

3.  Optimizing severe acute respiratory syndrome response strategies: lessons learned from quarantine.

Authors:  Tsung-Hsi Wang; Kuo-Chen Wei; Chao Agnes Hsiung; Susan A Maloney; Rachel Barwick Eidex; Drew L Posey; Wei-Hui Chou; Wen-Yi Shih; Hsu-Sung Kuo
Journal:  Am J Public Health       Date:  2007-04-05       Impact factor: 9.308

Review 4.  Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.

Authors:  Qing-He Nie; Xin-Dong Luo; Wu-Li Hui
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital.

Authors:  Hoe Nam Leong; Kwai Peng Chan; Ali S Khan; Lynette Oon; Su Yun Se-Thoe; Xin Lai Bai; Daniel Yeo; Yee Sin Leo; Brenda Ang; Thomas G Ksiazek; Ai Ee Ling
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

6.  SARS surveillance during emergency public health response, United States, March-July 2003.

Authors:  Stephanie J Schrag; John T Brooks; Chris Van Beneden; Umesh D Parashar; Patricia M Griffin; Larry J Anderson; William J Bellini; Robert F Benson; Dean D Erdman; Alexander Klimov; Thomas G Ksiazek; Teresa C T Peret; Deborah F Talkington; W Lanier Thacker; Maria L Tondella; Jacquelyn S Sampson; Allen W Hightower; Dale F Nordenberg; Brian D Plikaytis; Ali S Khan; Nancy E Rosenstein; Tracee A Treadwell; Cynthia G Whitney; Anthony E Fiore; Tonji M Durant; Joseph F Perz; Annemarie Wasley; Daniel Feikin; Joy L Herndon; William A Bower; Barbara W Klibourn; Deborah A Levy; Victor G Coronado; Joanna Buffington; Clare A Dykewicz; Rima F Khabbaz; Mary E Chamberland
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

7.  Clinical trials and novel pathogens: lessons learned from SARS.

Authors:  Matthew P Muller; Allison McGeer; Sharon E Straus; Laura Hawryluck; Wayne L Gold
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

8.  SARS and pregnancy: a case report.

Authors:  Corwin A Robertson; Sara A Lowther; Thomas Birch; Christina Tan; Faye Sorhage; Lauren Stockman; Clifford McDonald; Jairam R Lingappa; Eddy Bresnitz
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

9.  Severe acute respiratory syndrome-associated coronavirus in lung tissue.

Authors:  Tony Mazzulli; Gabriella A Farcas; Susan M Poutanen; Barbara M Willey; Donald E Low; Jagdish Butany; Sylvia L Asa; Kevin C Kain
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

10.  Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.

Authors:  Emily L C Tan; Eng Eong Ooi; Chin-Yo Lin; Hwee Cheng Tan; Ai Ee Ling; Bing Lim; Lawrence W Stanton
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.